Sign in to continue:

Thursday, February 26th, 2026

374Water Inc. Files Amended 8-K/A Report with SEC – Company Details, Address, and Stock Information (2026)

374Water Inc. Announces Board Committee Appointments in Amended 8-K Filing

374Water Inc. Announces Key Board Committee Appointments in Amended 8-K Filing

Key Points:

  • 374Water Inc. (NASDAQ: SCWO) has filed an amended Form 8-K/A with the SEC, dated February 25, 2026, amending its previous Form 8-K filed on February 9, 2026.
  • The amendment provides an important update regarding the appointment of Stephen McKnight to two critical board committees.
  • Mr. McKnight has been appointed to the Nominating and Corporate Governance Committee and the Compensation Committee, effective February 23, 2026.

Detailed Article

374Water Inc. Strengthens Board Governance with Committee Appointments

374Water Inc., a company listed on the Nasdaq Capital Market under the ticker SCWO, has issued an amendment to its previously filed Form 8-K, providing crucial updates regarding recent changes in its board structure.

On February 9, 2026, the company initially reported the appointment of Stephen McKnight to its Board of Directors. However, at that time, the Board had not determined which committees Mr. McKnight would serve on. In this newly filed amendment, dated February 25, 2026, 374Water Inc. has now confirmed that as of February 23, 2026, Stephen McKnight has been officially appointed to both the Nominating and Corporate Governance Committee and the Compensation Committee.

Why This Matters to Shareholders:

  • Enhanced Corporate Governance: The Nominating and Corporate Governance Committee is central to overseeing the company’s governance policies, evaluating director candidates, and ensuring high standards of board effectiveness and accountability.
  • Compensation Oversight: The Compensation Committee is responsible for setting and reviewing executive compensation policies, which directly impact the company’s ability to attract and retain top executive talent and align management interests with those of shareholders.
  • Potential Impact on Shareholder Value: Appointments to these committees, especially of a new director, can be price-sensitive. Changes in governance and compensation oversight are closely watched by institutional and retail investors as they may signal shifts in corporate strategy, risk management, or executive incentives.

Company Background:
374Water Inc., incorporated in Delaware and headquartered in Durham, North Carolina, is involved in the motors and generators industry. The company’s common stock (par value \$0.0001) is traded under the symbol SCWO on the Nasdaq Capital Market. The company’s business address is 701 W. Main Street, Suite 410, Durham, NC 27701, and it can be contacted at 440-601-9677.

Other Information:
– There are no disclosures of written communications, soliciting material, or pre-commencement tender offers or issuer tender offers related to this filing.
– The company is not classified as an “emerging growth company” under SEC rules.


Official Statement

The amended filing was signed by Danny Bogar, President and Chief Executive Officer of 374Water Inc., on February 25, 2026.


What Investors Should Watch For

  • The appointment of a new director to both the Nominating and Corporate Governance and Compensation Committees can have a material impact on how the company selects leadership and manages executive pay—two areas highly relevant to shareholder interests and company performance.
  • Investors should monitor subsequent announcements for any policy changes or strategic shifts that might follow these committee appointments.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisors before making any investment decisions. The author and publisher accept no liability for any losses incurred as a result of reliance on the information presented above.

View 374Water Inc. Historical chart here



AXT, Inc. SEC Filing 8-K: Financial Statements, Company Information, and Stock Data for 2024-2026

AXT, Inc. Reports Q4 and FY2025 Financial Results AXT, Inc. Announces Fourth Quarter and Fiscal Year 2025 Financial Results Key Highlights for Investors GAAP Net Loss: For Q4 2025, AXT, Inc. reported a net...

JBT Marel Reports Record 2025 Results, $3.8B Revenue, Strong Synergy Savings, and 2026 Growth Guidance

JBT Marel Corporation Reports Q4 and Full-Year 2025 Results, Sets 2026 Guidance JBT Marel Corporation Reports Record Q4 and Full-Year 2025 Results, Announces 2026 Outlook Key Highlights for Investors Record Orders and Revenue: Both...

Artiva Biotherapeutics, Inc. SEC Form 8-K Filing Details for January 2025 – Company Information, Trading Symbol, and Emerging Growth Status

Artiva Biotherapeutics, Inc. Announces Departure and Appointment of Chief Financial Officer San Diego, CA – February 24, 2026 – Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), a clinical-stage company specializing in biological products, has filed a...

   Ad